Nicotinamide: Potential for the prevention of type 1 diabetes?

Hormone and Metabolic Research

Volumn 28, Issue 7, 1996, Pages 361-364

  Gale, E A M ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

IDDM; nicotinamide; prevention

Indexed keywords

NICOTINAMIDE;

CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 0029957791     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979816     Document Type: Conference Paper

References (32)

1. American Diabetes Association: Position Statement. Prevention of Type 1 diabetes mellitus. Diabetes 39: 1151-1152 (1990)
2. Bingley, P. J.: Prediction of Diabetes: Interaction of risk markers in islet cell antibody positive family members: The first analysis of the ICARUS dataset. Diabetologia 37: A55 (Abstract) (1994)
3. Bingley, P. J., G. Caldas, R. Bonfanti, E. A. M. Gale: Nicotinamide and insulin secretion in normal subjects. Diabetologia 36: 675-677 (1993)
4. Bougneres, P. F., J. C. Corel, L. Castano, C. Boitard, J. P. Gardin, P. Landais, J. Hors, M. J. Mihatsch, M. Paillard, J. L. Chaussain, J. F. Bach: Factors associated with early remission of Type 1 diabetes in children treated with cyclosporine. N. Engl. J. Med. 318: 663-670 (1988)
5. Canadian-European Randomized Control Trial Group: Cyclosporin-induced remission of IDDM after early intervention: association with enhanced insulin secretion. Diabetes 37: 1574-1582 (1988)
6. Cetkovic-Cvrlje, M., S. Sandler, D. L. Eizirik: Nicotinamide and dexamethasone inhibit IL-1 induced nitric oxide production by RINnSF cells without decreasing mRNA expression for nitric oxide synthase. Endocrinology 133: 1739-1743 (1993)
7. Dulin, W. E., B. M. Wyse, M. S. Kalamazoo: Studies on the ability of compounds to block the diabetogenic activity of streptozotocin. Diabetes 18: 459-466 (1969)
8. Elliott, R. B., H. P. Chase: Prevention or delay of Type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia 34: 362-365 (1991)
9. Elliott, R. B., W. Cutfield, L. Escobar, N. Bibby: Successful prevention and cure of diabetes in the NOD mouse. IX Immunology of Diabetes Workshop (Abstract) (1988)
10. Gale, E. A. M., P. J. Bingley: Can we prevent IDDM? Diabetes Care 17: 339-344 (1994)
11. Gorsuch, A. N., K. M. Spencer, J. Lister, J. M. McNally, B. M. Dean, G. F. Bottazzo, A. G. Cudworth: Evidence for a long prediabetic period in Type 1 (insulin-dependent) diabetes mellitus. Lancet ii: 145-147 (1981)
12. Hayaishi, O., K. Ueda: Poly (ADP-ribose) and ADP ribosylation of proteins. Ann. Revg. Biochem. 46: 95-116 (1977)
13. Heller, S. P., Z. Q. Wang, E. F. Wagner, J. Radons, A. Burkle, K. Fehsel, V. Burkart, H. Kolb: Poly (ADP-ribose) polymerase dependent and independent toxicity of oxygen radicals and nitric oxide in murine islet cells. J. Biol. Chem. (in press, 1996)
14. Hoffer, A.: Safety, side effects and relative lack of toxicity of nicotinic acid and nicotinamide. Schizophrenia 1: 78-87 (1969)
15. Kazjmi, T., G. Yoshino, S. Baba: Pancreatic islet cell tumors found in rats given alloxan and nicotinamide. Endocrinol. Japon 27: 387-393 (1980)
16. Lazarow, A.: Protection against alloxan diabetes. Anat. Rec. 97: 353 (1947)
17. Mendola, G., R. Casamitjana, R. Gomis: Effect of nicotinamide therapy upon B-cell function in newly-diagnosed Type 1 (insulin-dependent) diabetic patients. Diabetologia 32: 160-162 (1989)
18. Nerup, J., T. Mandrup-Poulsen, J. Molvig, S. Helqvist, L. Wogensen, J. Egeberg: Mechanisms of pancreatic β-cell destruction in type 1 diabetes. Diabetes Care 11 (suppl. 1): 16-23 (1990)
19. Nomikos, I. N., S. J. Prowse, P. Carotenuto, K. J. Lafferty: Combined treatment with nicotinamide and desferrioxamine prevents islet allograft destruction in NOD mice. Diabetes 35: 1302-1304 (1986)
20. Petley, A., B. Macklin, A. G. Renwick, T. J. Wilkin: The pharmacokinetics of nicotinamide in humans and rodents. Diabetes 44: 152-155 (1995)
21. Pociot, F., J. I. Reimers, H. U. Andersen: Nicotinamide - biological actions and therapeutic potential in diabetes prevention. IDIG Workshop, Copenhagen, Denmark, 4-5 December 1992. Diabetologia 36: 574-576 (1993)
22. Rakieten, M. L., B. S. Gordon, A. Beaty, D. A. Cooney, R. D. Davis, P. S. Schein: Pancreatic islet cell tumors produced by the combined action of streptozotocin and nicotinamide. PSEBM 137: 280-283 (1971)
23. Shibata, K., T. Kawada, K. Iwai: Simultaneous micro-determination of nicotinamide and its major metabolites, N1-methyl-2-pyridone-5-carboxamide and N1-methyl-Pyridone-3-Carboxymide, by high performance liquid chromatography. Journal of Chromatography 424: 23-28 (1988)
24. Tjalve, H., E. Wilander: The uptake in the pancreatic islets of nicotinamide, nicotinic acid and tryptophan and their ability to prevent streptozotocin diabetes in mice. Acta Endocr. 83: 357-364 (1976)
25. Toth, B.: Lack of carcinogenicity of nicotinamide and isonicotinamide following lifelong administration to mice. Oncology 40: 72-75 (1983)
26. Vague, P., R. Picq, M. Bernal, V. Lassman-Vague, B. Vialettes: Effect of nicotinamide on the residual insulin secretion of Type 1 (insulin-dependent) diabetic patients. Diabetologia 32: 316-321 (1989)
27. Vague, P., B. Vialettes, V. Lassman-Vague, J. J. Vallo: Nicotinamide may extend remission phase in insulin-dependent diabetes. Lancet i: 619-620 (1987)
28. Vardi, P., L. Crisa, R. A. Jackson: Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of Type 1 (insulin-dependent) diabetic patients. Diabetologia 34: 93-102 (1991)
29. World Health Organization: Prevention of Diabetes Mellitus. Geneva: WHO 1-98 (1994)
30. Yamada, K., K. Nonaka, T. Hanafusa, A. Miyazaki, H. Toyoshima, S. Tarui: Preventive and therapeutic effects of large-dose nicotinamide injections on diabetes associated with insulitis. Diabetes 31: 749-753 (1982)
31. Yamagami, Y., A. Miwa, S. Takasawa, H. Yamamoto, H. Okamoto: Induction of rat pancreatic B-cell tumours by the combined administration of streptozotocin or alloxan and poly (ADP-ribose) synthetase inhibitors. Cancer Res. 45: 1845-1849 (1985)
32. Yonemura, Y., T. Takishima, K. Miwa, I. Miyazadi, H. Yamamota, H. Okamoto: Amelioration of diabetes mellitus in partially depancreatized rats by poly (ADP-ribose) synthetase inhibitors. Diabetes (1984)